ArticleBioinformatics (Oxford, England)2009
Approximate Bayesian feature selection on a large meta-dataset offers novel insights on factors that effect siRNA potency.
Article in Bioinformatics (Oxford, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Protection of animals against devastating RNA viruses using CRISPR-Cas13s.Molecular therapy. Nucleic acids · 2024Article
- A semi-supervised tensor regression model for siRNA efficacy prediction.BMC bioinformatics · 2015Article
- Computational design of artificial RNA molecules for gene regulation.Methods in molecular biology (Clifton, N.J.) · 2015Article
- Short-interference RNAs: becoming medicines.EXCLI journal · 2015Article
- In silico target-specific siRNA design based on domain transfer in heterogeneous data.PloS one · 2012Article
- Reconsideration of in-silico siRNA design based on feature selection: a cross-platform data integration perspective.PloS one · 2012Article
- Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.Frontiers in genetics · 2012Article
- DSIR: assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes.PloS one · 2012Article
- Predicting siRNA potency with random forests and support vector machines.BMC genomics · 2010Article
- Multi-task learning for cross-platform siRNA efficacy prediction: an in-silico study.BMC bioinformatics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
motivationShort interfering RNA (siRNA)-induced RNA interference is an endogenous pathway in sequence-specific gene silencing. The potency of different siRNAs to inhibit a common target varies greatly and features affecting inhibition are of high current interest. The limited success in predicting siRNA potency being reported so far could originate in the small number and the heterogeneity of available datasets in addition to the knowledge-driven, empirical basis on which features thought to be affecting siRNA potency are often chosen. We attempt to overcome these problems by first constructing a meta-dataset of 6483 publicly available siRNAs (targeting mammalian mRNA), the largest to date, and then applying a Bayesian analysis which accommodates feature set uncertainty. A stochastic logistic regression-based algorithm is designed to explore a vast model space of 497 compositional, structural and thermodynamic features, identifying associations with siRNA potency.
resultsOur algorithm reveals a number of features associated with siRNA potency that are, to the best of our knowledge, either under reported in literature, such as anti-sense 5' -3' motif 'UCU', or not reported at all, such as the anti-sense 5' -3' motif 'ACGA'. These findings should aid in improving future siRNA potency predictions and might offer further insights into the working of the RNA-induced silencing complex (RISC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.